Neuroinflammation in Parkinson's Disease: Triggers, Mechanisms, and Immunotherapies
- PMID: 33576313
- DOI: 10.1177/1073858421991066
Neuroinflammation in Parkinson's Disease: Triggers, Mechanisms, and Immunotherapies
Abstract
Parkinson's disease (PD) is a heterogeneous neurodegenerative disease involving multiple etiologies and pathogenesis, in which neuroinflammation is a common factor. Both preclinical experiments and clinical studies provide evidence for the involvement of neuroinflammation in the pathophysiology of PD, although there are a number of key issues related to neuroinflammatory processes in PD that remain to be addressed. In this review, we highlight the relationship between the common pathological mechanisms of PD and neuroinflammation, including aggregation of α-synuclein, genetic factors, mitochondrial dysfunction, and gut microbiome dysbiosis. We also describe the two positive feedback loops initiated in PD after the immune system is activated, and their role in the pathogenesis of PD. In addition, the interconnections and differences between the central and peripheral immune systems are discussed. Finally, we review the latest progress in immunotherapy research for PD patients, and propose future directions for clinical research.
Keywords: Parkinson’s disease; immunotherapies; microglia; neuroinflammation; α-synuclein.
Similar articles
-
Neuroinflammation and Parkinson's Disease-From Neurodegeneration to Therapeutic Opportunities.Cells. 2022 Sep 17;11(18):2908. doi: 10.3390/cells11182908. Cells. 2022. PMID: 36139483 Free PMC article. Review.
-
The Involvement of Neuroinflammation in the Onset and Progression of Parkinson's Disease.Int J Mol Sci. 2023 Sep 26;24(19):14582. doi: 10.3390/ijms241914582. Int J Mol Sci. 2023. PMID: 37834030 Free PMC article. Review.
-
Microglia Mediated Neuroinflammation in Parkinson's Disease.Cells. 2023 Mar 25;12(7):1012. doi: 10.3390/cells12071012. Cells. 2023. PMID: 37048085 Free PMC article. Review.
-
The role of Toll-like receptors and neuroinflammation in Parkinson's disease.J Neuroinflammation. 2022 Jun 6;19(1):135. doi: 10.1186/s12974-022-02496-w. J Neuroinflammation. 2022. PMID: 35668422 Free PMC article. Review.
-
Role of microglial metabolic reprogramming in Parkinson's disease.Biochem Pharmacol. 2023 Jul;213:115619. doi: 10.1016/j.bcp.2023.115619. Epub 2023 May 19. Biochem Pharmacol. 2023. PMID: 37211170 Review.
Cited by
-
Implications of COVID-19 in Parkinson's disease: the purinergic system in a therapeutic-target perspective to diminish neurodegeneration.Purinergic Signal. 2024 Mar 9. doi: 10.1007/s11302-024-09998-7. Online ahead of print. Purinergic Signal. 2024. PMID: 38460075 Review.
-
A New Strategy for the Regulation of Neuroinflammation: Exosomes Derived from Mesenchymal Stem Cells.Cell Mol Neurobiol. 2024 Feb 19;44(1):24. doi: 10.1007/s10571-024-01460-x. Cell Mol Neurobiol. 2024. PMID: 38372822 Free PMC article. Review.
-
New insight on microglia activation in neurodegenerative diseases and therapeutics.Front Neurosci. 2023 Dec 22;17:1308345. doi: 10.3389/fnins.2023.1308345. eCollection 2023. Front Neurosci. 2023. PMID: 38188026 Free PMC article. Review.
-
Myeloid-specific blockade of notch signaling alleviates dopaminergic neurodegeneration in Parkinson's disease by dominantly regulating resident microglia activation through NF-κB signaling.Front Immunol. 2023 Aug 23;14:1193081. doi: 10.3389/fimmu.2023.1193081. eCollection 2023. Front Immunol. 2023. PMID: 37680624 Free PMC article.
-
Astragaloside IV Inhibits Rotenone-Induced α-syn Presentation and the CD4 T-Cell Immune Response.Mol Neurobiol. 2024 Jan;61(1):252-265. doi: 10.1007/s12035-023-03566-7. Epub 2023 Aug 21. Mol Neurobiol. 2024. PMID: 37603153
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
